Oncolytics Biotech (TSE:ONC) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened

Oncolytics Biotech Inc. (TSE:ONC) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.

Oncolytics Biotech Price Performance

The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The company has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The firm has a 50 day simple moving average of C$14.90 and a 200-day simple moving average of C$14.90.

Insider Transactions at Oncolytics Biotech

In other news, Director Wayne Pisano acquired 30,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average price of C$1.16 per share, for a total transaction of C$34,800.00. Following the acquisition, the director owned 288,306 shares of the company’s stock, valued at C$334,434.96. This represents a 11.61% increase in their ownership of the stock. Also, Director Deborah Brown acquired 25,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of C$1.17 per share, for a total transaction of C$29,250.00. Following the acquisition, the director directly owned 109,851 shares in the company, valued at approximately C$128,525.67. This trade represents a 29.46% increase in their position. In the last three months, insiders have bought 289,232 shares of company stock worth $335,760. 3.82% of the stock is owned by corporate insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.